G2GBIO Inc (Ticker: 456160 KS) is a South Korean company specializing in medical and pharmaceutical research, focusing on a drug delivery system (DDS) platform for long-acting medicines. G2GBIO plans to list on the KOSDAQ on August 14, 2025, offering 900,000 new shares. The IPO was priced at KRW 58,000 per share, raising KRW 52.2 billion (approximately USD 37.7 million) and giving the company a market capitalization of around USD 225.5 million. The company reportedly plans to use the proceeds for research and development of its main pipelines, which include treatments for dementia, diabetes, and post-operative pain. The offering is managed by Mirae Asset Securities.